2. Immunology/Inflammation
  3. CD20

CD20

CD20 is a 33-37 kDa non-glycosylated protein expressed specifically on the surface of normal and malignant B lymphocytes, and belongs to the MS4A (membrane-spanning 4-domain family A) protein family. CD20 is a general B-cell marker expressed by the majority of B cells starting from late pre-B lymphocytes (it is not expressed by pro-B lymphocytes), and its expression is lost in terminally differentiated plasmablasts and plasma cells. Early experiments suggested that it was important in the regulation of human B-cell activation, proliferation, and Ca2+ transport. However, CD20-deficient mice appeared normal. Hence, the exact biological function of CD20 and its physiological ligand remain to be fully defined.240 Regardless of the uncertainty in the biological role of this antigen, it is a good target for cancer immunotherapy.

CD20 Related Products (16):

Cat. No. Product Name Effect Purity
  • HY-P9910
    Obinutuzumab
    Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
  • HY-P9961
    Ofatumumab
    Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes[1].
  • HY-P9913A
    Rituximab (anti-CD20)
    Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer[1].
  • HY-P9913
    Rituximab 99.85%
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
  • HY-P99024
    Glofitamab
    Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma[1][2].
  • HY-P99660
    Imvotamab Inhibitor
    Imvotamab (IGM-2323) is a CD20xCD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab is currently being developed for the treatment of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL)[1][2][3][4].
  • HY-P99952
    Ripertamab Inhibitor
    Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL)[1].
  • HY-P99776
    Plamotamab Inhibitor
    Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo[1][2].
  • HY-P99538
    Ublituximab Inhibitor
    Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects[1].
  • HY-P99326
    Tositumomab Inhibitor
    Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes[1].
  • HY-P99038
    Odronextamab 99.50%
    Odronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells[1].
  • HY-P99308
    Ocaratuzumab Inhibitor
    Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC)[1][2].
  • HY-P99501
    Zuberitamab Inhibitor
    Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma[1].
  • HY-P99855
    Divozilimab Inhibitor
    Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research[1].
  • HY-P99033
    Mosunetuzumab 99.05%
    Mosunetuzumab (BTCT-4465A) is a humanized, immunoglobulin G1-based bispecific antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs)[1].
  • HY-P99483
    Blontuvetmab Inhibitor
    Blontuvetmab (AT 004)is a caninized CD20 monoclonal antibody. Blontuvetmab can be used for the research of Canine B-cell lymphoma[1].